CBI’s Financial Series presents Tax Planning Strategies for Life Science Companies — a real-time assessment of corporate tax reform and its implications specific to pharmaceutical, biotech and medical device/technology companies. Industry insights and strategies are presented on key issues such as cash repatriation, deals, transactions and reporting.

Attendees Benefit From:

• CPE and CLE credits centered-on highly focused tax content,
  specific for life science companies
• Up to the minute insight on the implications of this landmark
  tax reform package
• Opportunity for peer-to-peer benchmarking
• Professional development

AGENDA SESSIONS WILL INCLUDE:

I. Nuances of Tax Reform and Potential Clarifying Guidance

II. Material Implications for Pharma and Biotech Manufacturers

III. Strategies for Cash Repatriation and Transition Tax Planning

IV. Tax Impact and Strategic Considerations for Deals/Acquisitions

V. Global Trends in Tax Policy